Partnering Goes Live in
- 00Days
- 00Hrs
- 00Mins
- 00Secs
17 - 19 March 2026
Austria CenterAustria Center, Vienna Michael KhanCEO at ARGONAUTE RNA LIMITEDSpeaker
Profile
CEO Dr Michael Khan, BSc, MBBS, PhD, FRCP. Formerly Head of Molecular Medicine at Warwick University. Formerly CMO of Silence Therapeutics. Senior Clinician and Dyslipidaemia expert. Has taken siRNA drugs from pre-clinical to Phase II. Runs Europe's leading Lp(a) screening service. Expert advisor to EC and NICE , establishing UK guidelines for management of cardiovascular diseases.
Agenda Sessions
Innovation Presentation: Bispecific-siRNA silencing synergistic target genes to prevent atherosclerotic cardiovascular disease (ASCVD) and fatty liver disease
, 12:05View Session